Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Nahid Sharmin; Chinyere Chioma Nganwuchu; Md Talat Nasim

doi:10.1016/j.tips.2021.04.002

Targeting the TGF-β signaling pathway for resolution of pulmonary arterial hypertension

Trends Pharmacol Sci. 2021 Jul;42(7):510-513. doi: 10.1016/j.tips.2021.04.002. Epub 2021 May 6.

Authors

Nahid Sharmin¹, Chinyere Chioma Nganwuchu², Md Talat Nasim³

Affiliations

¹ Translational Medicine Laboratory, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK; Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Dhaka, Dhaka-1000, Bangladesh.
² Translational Medicine Laboratory, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK.
³ Translational Medicine Laboratory, School of Pharmacy and Medical Sciences, Faculty of Life Sciences, University of Bradford, Bradford, West Yorkshire, BD7 1DP, UK; Centre for Health, Agriculture, and Socio-economic Advancements (CHASA), Lalmonirhat, Bangladesh. Electronic address: t.nasim@bradford.ac.uk.

PMID: 33966900
DOI: 10.1016/j.tips.2021.04.002

Abstract

Aberrant transforming growth factor-β (TGF-β) signaling activation is linked to pulmonary arterial hypertension (PAH). BMPR2 mutations perturb the balance between bone morphogenetic protein (BMP) and TGF-β pathways, leading to vascular remodeling, narrowing of the lumen of pulmonary vasculature, and clinical symptoms. This forum highlights the association of the TGF-β pathway with pathogenesis and therapeutic approaches.

Keywords: ALK5 inhibitor; BMP; TGF-β; pulmonary arterial hypertension; pulmonary vasculature.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Hypertension, Pulmonary* / drug therapy
Pulmonary Arterial Hypertension*
Signal Transduction
Transforming Growth Factors

Substances

Transforming Growth Factors